Evidence map›Paper›PMID 36773429›Full record

ArticleBiomaterials2023

Pharmacological ascorbate potentiates combination nanomedicines and reduces cancer cell stemness to prevent post-surgery recurrence and systemic metastasis.

Xiaomin Jiang, Jianqiao Liu, Jianming Mao, Wenbo Han, Yingjie Fan, Taokun Luo, Junjie Xia, Morten J Lee, Wenbin Lin

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Xiaomin JiangDepartment of Chemistry, The University of Chicago, Chicago, IL, 60637, USA.
Jianqiao LiuDepartment of Chemistry, The University of Chicago, Chicago, IL, 60637, USA.
Jianming MaoDepartment of Chemistry, The University of Chicago, Chicago, IL, 60637, USA.
Wenbo HanDepartment of Chemistry, The University of Chicago, Chicago, IL, 60637, USA.
Yingjie FanDepartment of Chemistry, The University of Chicago, Chicago, IL, 60637, USA.
Taokun LuoDepartment of Chemistry, The University of Chicago, Chicago, IL, 60637, USA.
Junjie XiaDepartment of Chemistry, The University of Chicago, Chicago, IL, 60637, USA.
Morten J LeeDepartment of Chemistry, The University of Chicago, Chicago, IL, 60637, USA.
Wenbin LinDepartment of Chemistry, The University of Chicago, Chicago, IL, 60637, USA; Department of Radiation and Cellular Oncology and Ludwig Center for Metastasis Research, The University of Chicago, 5758, S Maryland Ave, Chicago, IL, 60637, USA. Electronic address: wenbinlin@uchicago.edu.
University of Chicago · US

Funding

Nanoscale Coordination Polymers Co-deliver Chemotherapeutics and siRNAs for Efficacious Treatment of Resistant Ovarian CancerR01CA216436 · NCI · UNIVERSITY OF CHICAGO · PI LIN, WENBIN · 2018 to 2022
$2.1M
Targeted Nanomedicines with Synergistic Chemotherapeutics to Enhance Immunotherapy of Metastatic Colorectal CancerR01CA223184 · NCI · UNIVERSITY OF CHICAGO · PI LIN, WENBIN · 2018 to 2022
$1.8M
NCI NIH HHS R01 CA216436NCI NIH HHS R01 CA223184
6 · The paper itself

Abstract

Conventional chemotherapy targets proliferative cancer cells to halt tumor progression or regress tumors. However, the plasticity of tumor cells enables their phenotypical changes to acquire chemo-resistance, leading to treatment failure or tumor recurrence after a successful treatment course. Here, we report the use of high-dose pharmacologic ascorbate to potentiate treatment efficacy of nanoscale coordination polymers (NCPs) delivering two clinical combinations of chemotherapeutics, carboplatin/docetaxel and oxaliplatin/SN38, and to target metabolic plasticity of tumor cells. Combination treatments of high-dose ascorbate and NCPs overcome multi-drug resistance by significantly reducing the abundance of cancer stem cells (CSCs) in solid tumors, as evidenced by reduced expression of tumor pluripotency factors. The clearance of CSCs inhibits post-surgery recurrence and systemic metastasis in multiple mouse models of cancer.

Indexed as

Antineoplastic AgentsNeoplasmsAnimalsCell Line, TumorDocetaxelMiceNanomedicineNeoplastic Stem CellsOxaliplatinAntineoplastic AgentsDocetaxelOxaliplatinbioresposive nanoparticlesCancer stem cellschemotherapypharmacological ascorbatepost-surgery recurrencetumor metastasis

Identifiers

PMID36773429
PMCPMC9998353
OpenAlexW4319337543

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.